HappyLibrarian,
That road map you want can’t be shared until NWBO is done dealing with regulators about the regulators vision of the road map too. There are many more folks than just investors who are going to be impacted by what has been and is being discussed between NWBO, regulators and any potential partners.
Potential partners know that they could be scorched by Direct IF their products are not needed due to a sufficient immune response and memory developed without them. Just L has the potential to reduce the use of other treatments in patients that won’t gain any extra benefit from their use. This is why all the talk for now is about L and partners as if every patient will get all proposed combo and adjuvant activation treatments.
The reality of Direct and it’s potential crushing impact on big pharma when administered properly is something that many folks not well steeped in the science simply have never really considered a remote let alone likely possibility. Big pharma has become acutely aware of this, however, and they either make their move at the right time with Linda or get left behind in a swarm of folks willing to help be a part of the sea change. Best wishes.
Market Data 
Markets 
AI
